{"organizations": [], "uuid": "925936fcb1785c402b1a2b07fbc2081b1a3fd3b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-positiv/brief-azurrx-biopharma-announces-positive-preclinical-data-with-azx1103-idUSFWN1RV0JT", "country": "US", "domain_rank": 408, "title": "BRIEF-Azurrx Biopharma Announces Positive Preclinical Data With AZX1103", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.682, "site_type": "news", "published": "2018-04-18T20:00:00.000+03:00", "replies_count": 0, "uuid": "925936fcb1785c402b1a2b07fbc2081b1a3fd3b4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-positiv/brief-azurrx-biopharma-announces-positive-preclinical-data-with-azx1103-idUSFWN1RV0JT", "ord_in_thread": 0, "title": "BRIEF-Azurrx Biopharma Announces Positive Preclinical Data With AZX1103", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "azurrx biopharma inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - AzurRx BioPharma Inc:\n* AZURRX BIOPHARMA ANNOUNCES POSITIVE PRECLINICAL DATA WITH AZX1103\n* AZURRX BIOPHARMA INC - AZX1103 SHOWN TO BE SAFE AND BIOLOGICALLY ACTIVE IN A WELL-ESTABLISHED PRE-CLINICAL MODEL\n* AZURRX BIOPHARMA - PRECLINICAL STUDIES INVESTIGATED ORAL DELIVERY OF AZ1103 USING THREE CAPSULE FORMULATIONS, ALL APPEARING TO BE WELL TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T20:00:00.000+03:00", "crawled": "2018-04-19T14:58:00.011+03:00", "highlightTitle": ""}